Key clinical point: In patients with acute myeloid leukemia (AML), short-term posttransplant outcomes seemed similar in those who achieved first complete remission (CR1) with either first-line therapy with 5-azacitidine combined with venetoclax (aza-ven) or traditional intensive chemotherapy (IC).
Major finding: Rates of 12-month relapse-free survival and overall survival in aza-ven vs. IC groups were 58% vs. 54% and 63.2% vs. 70.8%, respectively. Cumulative incidences of acute graft versus host disease (GVHD) at 6 months and chronic GVHD at 12 months were 58% and 40% in the aza-ven group and 62% and 42% in the IC group, respectively.
Study details: This retrospective study included patients with AML who underwent allogeneic hematopoietic cell transplantation after achieving CR1 with either first-line aza-ven therapy (n = 24) or IC (n = 24).
Disclosures: No source of funding was identified. The authors declared no conflict of interests.
Source: Pasvolsky O et al. Ann Hematol. 2021(Oct 9). Doi: 10.1007/s00277-021-04693-8.